Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant

This study has been completed.
Information provided by:
Massachusetts General Hospital Identifier:
First received: April 2, 2007
Last updated: April 3, 2007
Last verified: April 2007

The purpose of this study is to describe the characteristics of patients with amyloidosis and severe heart failure being evaluated for cardiac and stem cell transplantation.


Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Characteristics of Patients With Systemic Amyloidosis and Severe Heart Failure Being Evaluated for a Sequential Cardiac and Autologous Stem Cell Transplantation

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Estimated Enrollment: 25
Study Start Date: March 2007
Estimated Study Completion Date: March 2007
Detailed Description:

Systemic amyloidosis is a progressive disease leading to organ failure and death. Treatment has improved survival with stem-cell transplantation. Unfortunately, patients with amyloidosis and severe heart failure are not eligible for stem-cell transplantation.

The average rate of survival for patients with amyloidosis who receive a heart transplant is decreased.

Previous trials have raised the possibility that survival may be increased in patients with amyloidosis, if chemotherapy and stem-cell transplantation is performed after a heart transplant.

We plan to review data of patients with amyloidosis and heart failure who were being evaluated for a heart transplant.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with amyloidosis
  • NYHA class III or IV heart failure
  • Patients undergoing heart transplant evaluation
  • Patients less than 18 years of age

Exclusion Criteria:

  • Patients who have unstable pulse and blood pressure
  Contacts and Locations
Please refer to this study by its identifier: NCT00456040

Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Marc J Semigran, MD Massachusetts General Hospital
  More Information

No publications provided Identifier: NCT00456040     History of Changes
Other Study ID Numbers: 2007-p-000302
Study First Received: April 2, 2007
Last Updated: April 3, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
heart failure
heart transplant
stem cell transplant

Additional relevant MeSH terms:
Heart Failure
Proteostasis Deficiencies
Metabolic Diseases
Heart Diseases
Cardiovascular Diseases processed this record on April 22, 2014